Investor Presentaiton
☐
Strategies for Japan:
World's 2nd largest pharma market
Generic market valued at $ 3.5 bn, growing at over 10%, with low generic penetration
of ~7% in value terms, 22% in volume terms (Source: IGPA)
Acquired Nippon Universal Pharma. Ltd. (now Zydus Pharma Japan - ZPJ), with a
marketing set-up and a small manufacturing facility
Plans to establish ZPJ as a generic player in Japan by introducing new products
through in-licensing route as well product registrations from India
Launched >25 new in-licensed products
in last two years
Recently launched Amlodipine in Japan to
become first Indian company to get a marketing
approval and launch a product manufactured
in India
Dedicated field force of >30 people to address
the requirements of the customers
Sales in Japan (Rs. Mio.)
422
219
▲ 44%
316
▲ 34%
FY 08-09
FY 09-10
FY 10-11
12View entire presentation